Cancer Research Technology Announces Recruitment of Prof. Lloyd Kelland as Head of Biology
London, UK, 29 March 2006 – Cancer Research Technology (“CRT”), specialists in oncology-focused development and commercialisation, today announced the successful recruitment of Prof. Lloyd Kelland as Head of Biology at CRT’s Development Laboratories.
Dr Clive Stanway, CRT’s Director of Technology Development, stated “We are delighted to have recruited Prof. Kelland to CRT. Our biotherapeutic and drug discovery programmes and the organisation as a whole will benefit greatly from his experience and expertise.”
Prof. Kelland will join CRT from Antisoma, where he is currently the Head of Research. Prior to Antisoma, Prof. Kelland was a Principal Investigator at the Cancer Research UK Centre for Cancer Therapeutics at the prestigious Institute of Cancer Research. In these positions Prof. Kelland has been instrumental in the development of a number of anti-cancer agents currently in advanced clinical development and has published in excess of 150 papers in the field of preclinical cancer drug development.
Prof. Kelland’s experience of both academic and commercial-based drug development will be invaluable for CRT, an organisation that through collaboration builds on academic research to create attractive commercial partnerships.
---ends---
About CRT’s Development Laboratories
CRT’s Development Laboratories are situated within the Wolfson Institute for Biomedical Research at University College London. The laboratories are staffed with industrially trained and experienced scientists with core competences in molecular and cellular biology, assay design and high throughput screening, medicinal chemistry and early pharmacology. CRT’s Development Laboratories develop biotherapeutics and small molecule inhibitors from academic discoveries through to in vivo proof of concept studies prior to out-licensing, thereby facilitating industrial preclinical development.
About Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.cancertechnology.com.
|
